तुलना करने के लिए मीट्रिक्स | SLDB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSLDBपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.0x | −2.4x | −0.6x | |
PEG अनुपात | −0.12 | −0.09 | 0.00 | |
क़ीमत/बुक | 3.9x | 2.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 9.3x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 122.2% | 182.7% | 48.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.8% | 5.8% | अनलॉक करें |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.